INMiND consortium well on track to reach its ambitious goals

For the third time the INMiND consortium came together to discuss the project’s key developments focussing on dynamics of microglia activation and its contribution to neuronal degeneration and regeneration by molecular imaging technologies in vivo under various paradigms including immunomodulation.

On February 26 and 27, 70 researchers ranging from basic scientists to clinicians and from students to principle investigators from 13 countries came together in Bonn, Germany. The work package leaders of the nine scientific work packages and the training work package presented the latest results and discussed further steps to be undertaken to research the ambitious aims of the project in the coming two years. In addition Prof Birnbacher (University of Düsseldorf) and Dr Fuchs (University of Bonn) members of the Ethical Advisory Committee joined the meeting to enrich the discussions with their critical review and valuable input concerning the project’s ethical issues.

During the individual scientific work package presentations and discussions it became clear that substantial progress has been made during the first 3 years of the project in all research fields. Moreover, the training offer organised by the training work package attracted so far more than 270 researchers, not only from within the INMiND consortium but also from external academic and non-academic research institutes. These researchers took the opportunity to participate in high level trainings and broaden their skills in a wide range of research topics in the field of neuroinflammation and neurodegeneration (NIND) imaging.
Among the main scientific results discussed during the third annual meeting were the identification and the biological and radiopharmaceutical validation of 4 imaging targets that might be good candidates for the development of M2-specific microglia radiotracers. Lead compounds will be radiolabelled and the developed ligands in detailed studied for their in vitro and in vivo performance in the next period. Consensus protocols have been established for several in vitro and vivo applications to ensure harmonisation and increase comparability of results from partner institutions. Working groups per animal model were established to coordinate experimental protocols and result analysis. A whole range of contrast agents (radiotracers, but also MRI and OI agents) directed to several NIND targets have been developed, produced and tested to unravel the molecular mechanisms involved in NIND, not only in various animal models but also in patients, both in normal disease progression and under pharmacological manipulation.

Like the years before, the INMiND Annual Meeting offered perfect opportunity for all researchers to foster communication and to identify collaboration possibilities between different partner institutions.

INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313